| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.48▼ | 0.48▼ | 0.48▼ | 0.50▼ | 0.52▼ |
| MA10 | 0.49▼ | 0.49▼ | 0.49▼ | 0.51▼ | 0.52▼ |
| MA20 | 0.50▼ | 0.50▼ | 0.50▼ | 0.53▼ | 0.54▼ |
| MA50 | 0.50▼ | 0.51▼ | 0.52▼ | 0.50▼ | 0.73▼ |
| MA100 | 0.53▼ | 0.54▼ | 0.54▼ | 0.56▼ | 1.09▼ |
| MA200 | 0.54▼ | 0.52▼ | 0.50▼ | 0.71▼ | 4.60▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.002▼ | -0.002▼ | -0.002▼ | -0.007▼ | 0.010▲ |
| RSI | 42.189▼ | 41.184▼ | 41.744▼ | 39.112▼ | 39.839▼ |
| STOCH | 25.445 | 21.334 | 20.878 | 36.795 | 57.265 |
| WILL %R | -72.447 | -72.447 | -72.447 | -89.272▼ | -69.165 |
| CCI | -83.616 | -90.562 | -92.549 | -145.852▼ | -65.592 |
|
Thursday, September 17, 2026 01:38 PM
Detailed price information for Pasithea Therapeutics Corp (KTTA-Q) from The Globe and Mail including charting and trades.
|
|
Monday, September 14, 2026 05:53 AM
Pasithea Therapeutics will present first clinical data from PAS-004 Phase 1/1b trial in neurofibromatosis type 1 at the 2026 ...
|
|
Saturday, August 22, 2026 02:40 PM
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 28/09/26 | 0.4809 | 0.493 | 0.4656 | 0.4799 | 143,086 |
| 25/09/26 | 0.50 | 0.5097 | 0.4852 | 0.4992 | 94,762 |
| 24/09/26 | 0.5033 | 0.5298 | 0.5033 | 0.5137 | 85,147 |
| 23/09/26 | 0.508 | 0.52 | 0.5017 | 0.5127 | 114,004 |
| 22/09/26 | 0.5298 | 0.5298 | 0.495 | 0.5141 | 164,988 |
| 21/09/26 | 0.51 | 0.5166 | 0.4949 | 0.5104 | 67,620 |
| 18/09/26 | 0.525 | 0.55 | 0.4876 | 0.5237 | 482,375 |
| 17/09/26 | 0.49 | 0.5141 | 0.474 | 0.5067 | 238,004 |
| 16/09/26 | 0.50 | 0.51 | 0.49 | 0.49 | 79,829 |
| 15/09/26 | 0.4982 | 0.5288 | 0.491 | 0.50 | 280,399 |
|
|
||||
|
|
||||
|
|